Header cover image

Japanese Pharmaceuticals & Biotech Established, Profitable and Undervalued

UPDATED Aug 10, 2022

Over $1bn in market cap, profitable and undervalued based on cash flows.

8 companies
CompanyLast Price7D Return1Y ReturnMarket CapAnalysts TargetValuationGrowthDiv Yield
4568Daiichi Sankyo CompanyJP¥3,632.006.6%59.9%JP¥7.0tJP¥4,250.00PE137.6xE33.3%0.7%
4519Chugai PharmaceuticalJP¥3,784.002.4%-7.6%JP¥6.2tJP¥4,617.50PE16xE0.5%2.0%
4502Takeda PharmaceuticalJP¥3,782.001.7%3.7%JP¥5.8tJP¥4,561.33PE29.6xE7.5%4.8%
4503Astellas PharmaJP¥2,014.500.7%12.2%JP¥3.7tJP¥2,600.00PE31.1xE17.2%3.0%
4578Otsuka HoldingsJP¥4,619.000.7%-0.5%JP¥2.5tJP¥4,809.09PE24.1xE3.9%2.2%
4507ShionogiJP¥6,862.001.3%5.5%JP¥2.1tJP¥8,010.83PE17.7xE1.7%1.7%
4151Kyowa KirinJP¥3,120.002.5%-11.0%JP¥1.7tJP¥3,624.55PE26.9xE11.2%1.5%
4528Ono PharmaceuticalJP¥3,364.001.1%34.6%JP¥1.6tJP¥3,715.00PE19.1xE2.9%2.0%
Page 1 of 1